Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Total Liabilities (2016 - 2025)

Myriad Genetics (MYGN) has disclosed Total Liabilities for 16 consecutive years, with $338.6 million as the latest value for Q4 2025.

  • Quarterly Total Liabilities rose 3.71% to $338.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $338.6 million through Dec 2025, up 3.71% year-over-year, with the annual reading at $338.6 million for FY2025, 3.71% up from the prior year.
  • Total Liabilities for Q4 2025 was $338.6 million at Myriad Genetics, down from $355.3 million in the prior quarter.
  • The five-year high for Total Liabilities was $465.7 million in Q3 2023, with the low at $262.8 million in Q2 2022.
  • Average Total Liabilities over 5 years is $354.3 million, with a median of $347.1 million recorded in 2024.
  • The sharpest move saw Total Liabilities plummeted 42.61% in 2022, then surged 71.99% in 2023.
  • Over 5 years, Total Liabilities stood at $352.9 million in 2021, then dropped by 11.33% to $312.9 million in 2022, then grew by 16.11% to $363.3 million in 2023, then decreased by 10.13% to $326.5 million in 2024, then increased by 3.71% to $338.6 million in 2025.
  • According to Business Quant data, Total Liabilities over the past three periods came in at $338.6 million, $355.3 million, and $289.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.